Floatz Rating
B63/100
Confidence
Indicative
Sponsor
The Nethersole School of Nursing
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06425133CT.gov Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers | — | Recruiting | — | — | — |
NCT05462613CT.gov Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05411718CT.gov A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome | — | Recruiting | — | — | — |
NCT05158374CT.gov Molecular Effects of Aspirin & Metformin on Colonic Epithelium | — | Withdrawn | — | — | — |
NCT05402124CT.gov The Colorectal Cancer Chemoprevention Acceleration and Improvement Platform (CRC-CHAMP) Study | — | Unknown | — | — | — |
NCT04534218CT.gov Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT03603366CT.gov Study to Evaluate How Patients Regard the Benefits and Risks of Low-dose Aspirin for the Prevention of Heart and Blood Vessels Disease and for the Prevention of Cancer of the Colon and Rectum | — | Completed | — | — | — |
NCT03957902CT.gov Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer | — | Recruiting | — | — | — |
NCT03904732CT.gov Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU | — | Completed | — | — | — |
NCT03638297CT.gov PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | — | Unknown | — | — | — |
Show 9 more trialsShow fewer
NCT02945033CT.gov Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk | — | Active Not Recruiting | — | — | — |
NCT03326791CT.gov Aspirin in Colorectal Cancer Liver Metastases | — | Active Not Recruiting | — | — | — |
NCT02647099CT.gov Adjuvant Low Dose Aspirin in Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT02607072CT.gov Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial | — | Unknown | — | — | — |
NCT02125409CT.gov Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action | — | Unknown | — | — | — |
NCT00565708CT.gov Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers | — | Unknown | — | — | — |
NCT00062023CT.gov Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer | — | Terminated | — | — | — |
NCT00033319CT.gov Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps | — | Unknown | — | — | — |
NCT00272324CT.gov Aspirin/Folate Prevention of Large Bowel Polyps | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aspirin (this asset) | The Nethersole School of Nursing | P3 | B · 63 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Aspirin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P4 | A · 83 |
| Coronary Artery Disorder | — | P4 | BBB · 79 |
| Cardiovascular Disorder | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Aspirin in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/aspirin-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →